Market Access VCs upbeat about European life sciences market, despite unce... It has been a curious start to the year for pharma and biotech investment.
R&D Investing in the gleams of positivity and hope for life scie... In this third instalment of the five-part, festive series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Mark Andrews, investment director of life sciences funds at Brit
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
